- Tiziana Life Sciences said it had generated positive results from a clincial trail assessing the safety of a treatment for hepatocellular carcinoma, the most common form of liver cancer.

Overall, treatment with Milciclib was well-tolerated and no drug-related deaths were recorded, the company said.

Secondary endpoints of efficacy including progression-free survival and time to progression were currently being evaluated and would subsequently be reported.

Among the 28 evaluable patients, 14 completed the six-month duration study.

Oral treatment with Milciclib was well-tolerated with manageable toxicities.

The most frequent adverse events such as diarrhea, ascites, nausea, fatigue, asthenia, fever, ataxia, headache, and rash were manageable.

Nine out of the 14 patients, after completing the six-month trial period, requested to continue the treatment under compassionate use and were approved by their respective ethical committees.

At 8:22am: [LON:TILS] Tiziana Life Sciences Plc share price was +6p at 66p

Story provided by